Medicaroid has obtained CE marking for its hinotori Surgical Robot System under the EU's Medical Device Regulation, allowing it to market the system across EU member states and select non-EU countries. This approval is a crucial part of Medicaroid's strategy to expand internationally beyond Japan and the Asia-Pacific region.
The hinotori Surgical Robot System was initially approved for manufacture and sale in Japan in 2020 and has since gained regulatory approvals in Singapore, Malaysia, and Vietnam. The recent CE marking enables Medicaroid to enter the European, Middle Eastern, and African markets, which is vital for the company's growth and the global adoption of medical robotics.
Looking ahead, Medicaroid aims to leverage its new certification to enhance its presence in the EMEA region. The company established Medicaroid Europe GmbH in Germany in 2020 to facilitate its commercial operations. No further timeline was disclosed at the time of publication.
Editor's Note
Medicaroid's CE marking for the hinotori Surgical Robot System underscores the growing trend of medical robotics in Europe. As healthcare providers increasingly adopt advanced surgical technologies, companies like Medicaroid are positioned to play a significant role in enhancing patient outcomes and operational efficiency in hospitals.
Leave a comment